
 | ²¹Ç®Ê»ÍÑÆ°Ãí²½³ØÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿Å¾°ÜÀ´Î´â¤Î¾ÉÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤ¬ÁÕ¸ú¤·¤¿stage IVÀ¼Ìç¾å¹¢Æ¬´â¤Î°ìÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤ¬ÁÕ¸ú¤·¤¿¥Û¥ë¥â¥óÄñ¹³ÀµðÂçÁ°Î©Á£´â ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤ¬Ãø¸ú¤·¤¿¸¶È¯ÉÔÌÀ¹üž°Ü¤Î°ìÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤ¬Ãø¸ú¤ò¼¨¤·¤¿»éËÃÆù¼ð¤Î°ìÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤ¬Í¸ú¤Ç¤¢¤Ã¤¿¶É½ê¿Ê¹Ô»ÒµÜ´â¤Î°ìÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤ¬ÍÍѤǤ¢¤Ã¤¿²¼»èMFH¤Î°ìÎã | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤ¬ÍÍѤǤ¢¤Ã¤¿Æý´â¤Î°ìÎã | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤǶɽêÀ©¸æ¤Ç¤¤¿MFH¤Î°ìÎã | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤǸú²Ì¤ÎÆÀ¤é¤ì¤¿¶É½ê¿Ê¹Ôç¹´â¤Î°ìÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤÇÀÔ¿ñ¿»½á¤òËɻߤǤ¤¿¶»ÊÉ¿»½á·¿ÇÙ´âÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤˤÆÃø¸ú¤¬ÆÀ¤é¤ì¤¿ç¯æù´âͳÍè¤ÎµðÂç¤Ê±¦Â¦Ä²¹üž°ÜÀ¼ðáç ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤˤè¤ê5ǯÀ¸Â¸¤ò²Ì¤¿¤·¤¿¹âÎð¼ÔºÆÈ¯ç¯æù´â¤Î°ìÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŸå15ǯ¤ò·Ð²á¤·¤¿ºÆÈ¯Æý´â¾ÉÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŸåÀÚ½ü¤µ¤ì¡¤ÁÈ¿¥³ØÅª¸¡ºº¤Ë¤ÆCR¤Ç¤¢¤Ã¤¿Pancoast·¿ÇÙ´â¤Î°ìÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®Ê»ÍÑÊü¼ÍÀþÎÅË¡¤ò»Ü¹Ô¤·¤¿½½Æó»ØÄ²´â½Ñ¸åºÆÈ¯¤Î°ìÎã ¢¡ | ²¹Ç®¼£Îо |
 |
 | ²¹Ç®Êü¼ÍÀþ¼£ÎŸå¤Ëư̮ºÉÀò½Ñ¤ò¹Ô¤Ã¤¿´Î´â¤Î1Îã ¢¡ | 19-Supplement¡¡¶ ¾ |
 |
 | ²¹Ç®Êü¼ÍÀþÎÅË¡¤¬Ãø¸ú¤·¤¿ºÆÈ¯»éËÃÆù¼ð¤Î°ìÎã ¢¡ | ²¹Ç®¼£Îо |
 |
 | ²¹Ç®ÎÅË¡¤¬ÁÕ¸ú¤·¤¿¸åÊ¢Ëì³êËìÆù¼ð¤Î1Îã¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | 19-Supplement¡¡¶ ¾ |
 |
 | ²¹Ç®ÎÅË¡¤¬Ãø¸ú¤·¤¿µðÂç½½Æó»ØÄ²´â¤Î°ìÎã¡¡¡¦¡¦¡¦²¹Ç®ÎÅË¡¤¬Ãø¸ú¤·¤¿µðÂç½½Æó»ØÄ²´â¤Î°ìÎ㡦¡¦ ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®ÎÅË¡¤¬Ãø¸ú¤·¤¿ÀÚ½üÉÔǽľIJ´â¤Î°ìÎã¡¡¡¦¡¦¡¦²¹Ç®ÎÅË¡¤¬Ãø¸ú¤·¤¿ÀÚ½üÉÔǽľIJ´â¤Î°ìÎ㡦¡¦ ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¹Ç®ÎÅË¡¤È²½³ØÎÅË¡¤ÎÊ»ÍѤÇQOLµÚ¤Ó²èÁü½ê¸«¤¬²þÁ±¤µ¤ì¤Æ¤¤¤ëËö´ü´â´µ¼Ô¤Î1Îã ¢¡ | 19-Supplement¡¡¶ ¾ |
 |
 | ²¹Ç®ÎÅË¡¤È½¸³ØÅª¼£ÎŤ¬ÁÕ¸ù¤·¤¿Â¿Â¡´ïž°Ü¤òȼ¤¦¿Ê¹ÔľIJ´â¤Î1Îã | 22²ó¡¡Âç²ñ |
 |
 | ²¹Ç®ÎÅË¡¤È½¸³ØÅª¼£ÎŤ¬ÁÕ¸ù¤·¤¿Â¿Â¡´ïž°Ü¤òȼ¤¦¿Ê¹ÔľIJ´â¤Î1Îã | 21-3 |
 |
 | ²¹Ç®ÎÅË¡¤Ë¤è¤ê¼ðáî¤Î½Ì¾®¤¬¤¨¤é¤ì¤¿Ë¦Áã¾õÆðÉôÆù¼ð¤Î1Îã ¢¡ | 21-Supplement ¶ ¾ |
 |
 | ²¹Ç®ÎÅË¡¤Î´Ç¸î:°å»Õ¡¦´Ç¸îÉØÏ¢Ííɼ¤òÍѤ¤°Û¾ï¤ÎÁá´üȯ¸«¤ËÅØ¤á¤Æ ¢¡ | 15-Supplement¡¡µ ¾ |
 |
 | ²¹Ç®ÎÅË¡¤Î´Ç¸î:´Ç¸îµÏ¿ÍÑ»æ¤ò¤¢¤ë¤¦¤ÄÉ´µ¼Ô¤Ë»ÈÍѤ·¤Æ ¢¡ | 15-Supplement¡¡µ ¾ |
 |
 | ²¹Ç®ÎÅË¡¤Î¼§ÀÂÎÊ»ÍѤˤè¤ë¸ú²ÌÁý¶¯¤Ë´Ø¤¹¤ë´ðÁÃŪ¸¦µæ ¢¡ | 19-Supplement¡¡µ ¾ |
 |
 | ²¹Ç®ÎÅË¡¸å¤ÎÈÕ´üͳ²»ö¾Ý¤Î¸¡Æ¤¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | 19-Supplement¡¡¶ ¾ |
 |
 | ²¹Ç®ÎÅˡñÆÈ¤ÇÊâ¹Ô²Äǽ¤È¤Ê¤Ã¤¿¼ðáî·ÁÀ®·¿¹üž°Ü¾ÉÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | ²¼°öƬ¡¦¿©Æ»Æ±»þÀ½ÅÊ£´â¾ÉÎã¤ÎÎ×¾²Åª¸¡Æ¤ ¡½ ¹¢Æ¬,¿©Æ»²¹Â¸¤òÌܻؤ·¤Æ ¡½ | 56-04 |
 |
 | ²¼°öƬ´â T1, T2¾ÉÎã¤Î¼£ÎÅÀ®ÀÓ ¡½ºÆÈ¯¾ÉÎã¤Î¸¡Æ¤¡½ ¢¡ | £±£°·î£±Æü£Õ£Ð ¾ |
 |
 | ²¼°öƬ´âT3¡¦T4¾ÉÎã¤Î¼£ÎÅÀ®ÀÓ¡¡¡¦¡¦¡¦ÂоݤÈÊýË¡¡¡114Îã
¡¡°öƬ٨ʿ¾åÈé´â¡¡°ì¼¡º¬¼£¾ÉÎãT3¡¦T4
¹Í»¡¡¦¡¦ ¢¡ | £±£°·î£±Æü£Õ£Ð ¾ |
 |
 | ²¼°öƬ´â¤ÎÁá´ü¿ÇÃǤβÄǽÀ¡¡¡Ý²¼°öƬ´â¤Î¼£ÎÅÀïά ¢¡ | £±£°·î£±Æü£Õ£Ð ¾ |
 |
 | ²¼°öƬ´âº¬¼£¼ê½Ñ¤Ë¤ª¤±¤ëÀÚ½üÈϰϤÎÀ°¹çÀ ¡Ý²¼°öƬ´â¤Î¼£ÎÅÀïά ¢¡ | £±£°·î£±Æü£Õ£Ð ¾ |
 |
 | ²¼°öƬ´â¼£ÎŤÎÊÑÁ«¤ÈŸ˾¡¡¡¦¡¦¡¦²¼°öƬ´â¤Î¼£ÎÅÀ®ÀÓ..
¹ÈϰÏÀÚ½ü¡¡
µ¡Ç½²¹Â¸¡¡ÌäÂꡦ¡¦ ¢¡ | °öƬ´â ¾ |
 |
 | ²¼°öƬ´â¼£ÎŸå¤ËÀ¸¤¸¤¿Êü¼ÍÀþÀÔ¿ñ¾ÉÎã¡¡¡¦¡¦¡¦¾ÉÎã:50ºÐ,ÃËÀ stageIVA
ĶÁªÂòŪưÃí²½³ØÎÅË¡ ¥·¥¹¥×¥é¥Á¥ó ¥Ô¥é¥ë¥Ó¡¦¡¦ ¢¡ | °öƬ´â ¾ |
 |
 | ²¼°öƬ´â¾È¼Í¡¦²½³ØÆ±»þÊ»ÍÑÎÅË¡¤Îº¬¼£À ¡Ý²¼°öƬ´â¤Î¼£ÎÅÀïά ¢¡ | £±£°·î£±Æü£Õ£Ð ¾ |
 |
 | ²¼°öƬ¿À·Ð¾ä¼ðÎã¡¡¡¦¡¦¡¦¾ÉÎã1:49ºÐ,ÃËÀ¡¦¡¦ ¢¡ | £¸·îÂè3½µ(10Æü¡Ë ¾ |
 |
 | ²¼³Ü¹üÆâ¤ÎXÀþÆ©²áÀÉÂÊѤ«¤éȯ¸«¤µ¤ì¤¿Â¿È¯À¹ü¿ñ¼ð¤Î1Îã ¢¡ | ¹ü¿ñ¼ð ¾ |
 |
 | ²¼³Ü»õÆù¤Ëž°Ü¤·¤¿´ÎºÙ˦´â¤Î1Îã¡¡¡¦¡¦¡¦73ºÐ,ÃËÀ¡¡
¡¡´ÎºÙ˦´â¤¬²¼³Ü»õÆù¤Ëž°Ü¡¡
¡¡¡¦¡¦ ¢¡ | ¸ý¹Ð´â ¾ |
 |
 | ²¼·ì¤ò·Àµ¡¤Ë, ¾®Ä²XÀþ¸¡ºº¤Çȯ¸«¤µ¤ì¤¿¶õIJuncommitted type gastrointestinal stromal tumor¤Î1Îã ¢¡ | GIST ¾ |
 |
 | ²¼»è¥ê¥ó¥ÑÉâ¼ð¤Î¼£ÎÅË¡¤Î³µÀâ¡¡¡¦¡¦¡¦³µÇ°¡¡
ÉÂÍýÀ¸Íý¡¡
Î×¾²½ê¸«
¡¡¡¦¡¦¡¦¡¦¡¡
¼£ÎÅ¡¦¡¦ ¢¡ | £²·îÂ裴½µ¡§£²£µÆü¡Ê¶â¡Ë ¾ |
 |
 | ²¼»è»éËÃÆù¼ð¤ËÂФ¹¤ë½ÑÁ°Êü¼ÍÀþ²¹Ç®ÎÅË¡¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | 15-Supplement¡¡µ ¾ |
 |
 | ²¼»èËãáã¤òȼ¤¦Ä¾Ä²´âÂè»Í¹øÄÇÄǵݹüž°Ü¤Î°ìÎã ¢¡ | 21-Supplement µ ¾ |
 |
 | ²¼ÂܤËÈé²¼·ëÀá»éËòõ»à¤òȼ¤Ã¤¿ç¹Á£Ë¼ºÙ˦´â¤Î1ÀÚ½üÎã | 39-03 |
 |
 | ²¼ÂçÀÅÌ®¡¦´ÎÀÅÌ®¿»½á¤ò¤¤¿¤·¤¿Å¾°ÜÀ´Î´â¤ËÂФ¹¤ë¼£ÎÅÀ®ÀÓ ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | ²¼ÂçÀÅÌ®¤Ë¿»½á¤·¤¿ÃÀ´ÉºÙ˦´â¡¦Å¾°ÜÀ´Î´â¤ËÂФ¹¤ë³°²ÊŪ¼£ÎÅ ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | ²¼ÂçÀÅÌ®¤ËÀܤ·¤¿ºÆÈ¯´Î´â¤ËÂФ·¤Æ¥Þ¥¤¥¯¥íÇȶŸÇÎÅË¡¡¢¥¨¥¿¥Î¡¼¥ëÃíÆþÊ»ÍÑÎÅË¡¤¬Ãø¸ú¤·¤¿ 1 Îã ¢¡ | ´Î¡´â ¾ |
 |
 | ²¼ÂçÀÅÌ®¹çÊ»ÀÚ½ü¤òÍפ·¤¿µðÂç¸åÊ¢ËìÊ¿³ê¶ÚÆù¼ð¤Î1ÀÚ½üÎã | 39-03 |
 |
 | ²¼Éô°ß´â¤Î¼ê½ÑË¡¡¡¡¦¡¦¡¦½Ñ¼°¤ÎÁªÂò
cM´â(Î×¾²¿ÇÃǤ¬Ç´ËìÆâ´â)¤ËÂФ¹¤ë½Ñ¼°
¡¦¡¦¡¦¡¦
½Ñ¼°¤Î¼ÂºÝ
¡¦¡¦ ¢¡ | £²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾ |
 |
 | ²¼ÉôľIJ¡¦æêÌç´É´â¤ËÂФ¹¤ë¿¼¡¦Àõ³°æêÌç³çÌó¶Ú¹çÊ»ÀÚ½ü¤òȼ¤¦µæ¶Ë¤ÎæêÌ粹¸½Ñ ¢¡ | £²·îÂ裴½µ¡§£²£µÆü¡Ê¶â¡Ë ¾ |
 |
 | ²¼ÉôľIJ´â¤ËÂФ¹¤ë¥»¥ó¥Á¥Í¥ë¥ê¥ó¥ÑÀáÀ¸¸¡¤òÍѤ¤¤¿·ÐÀç¹üŪľIJÀÚ½ü½Ñ¤Î»î¤ß ¢¡ | ¥»¥ó¥Á¥Í¥ë¥ê¥ó¥ÑÀá ¾ |
 |
 | ²¼ÉôľIJ´â¤ËÂФ¹¤ë³çÌó¶Ú²¹Â¸¼ê½Ñ¡¡¡¦¡¦¡¦¼ê½Ñ¼êµ»¡¡
¡¡Ä¾Ä²¤ÎÇíÎ¥¡¦¼øÆ°¡¡
¡¡¡¦¡¦¡¦¡¦
¡¡¡¦¡¦¡¦¡¦
¼ê½ÑÀ®ÀÓ¡¡
½Ñ¸åÇÓÊØ¡¦¡¦ ¢¡ | £²·îÂ裴½µ¡§£²£µÆü¡Ê¶â¡Ë ¾ |
 |
 | ²¼ÉôľIJ´â¤ËÂФ¹¤ëÊü¼ÍÀþ¡¦²¹Ç®ÎÅË¡¤Î¸ú²Ì¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | 19-Supplement¡¡µ ¾ |
 |
 | ²¼Î¡¡¦ÊØÈë ¡¡¡Ý´â¼£ÎŤˤª¤±¤ëͳ²È¿±þÂкö ¢¡ | £¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾ |
 |
 | ²¼Î¡Âкö¡¡¡¦¡¦¡¦¿·¤·¤¤Í³²È¿±þÂкö¡¦¡¦ ¢¡ | ÉûºîÍÑ Â¾ |
 |
 | ²½³ØÊü¼ÍÀþÎÅË¡¤Ë¤è¤ëCR¸å¤Î¶É½êºÆÈ¯¤ËÂФ·³°²ÊŪ¼£ÎŤò¹Ô¤Ã¤¿¾®ºÙ˦ÇÙ´â¤Î1Îã ¢¡ | ¾®ºÙ˦´â ¾ |
 |
 | ²½³ØÍ½ËÉ¡¡¡¦¡¦¡¦¦Â-¥«¥í¥Á¥ó¡¡ÇÙ´â¿ÇΚݺǶá¤ÎÏÃÂê¡Ý¡¦¡¦ ¢¡ | ÇÙ´â ¾ |
 |
 | ²½³ØÎÅË¡¡¡¡¦¡¦¡¦¡¦ÇÙ¾®ºÙ˦´â¤Î²½³ØÎÅË¡¡¡
ɸ½à²½³ØÎÅË¡¡¡£Ì£Ä¾ÉÎã¤ËÂФ¹¤ëÊü¼ÍÀþ²½³ØÎÅË¡¡¡
¡¦ÇÙ¡¦¡¦ ¢¡ | ÇÙ´â ¾ |
 |
 | ²½³ØÎÅË¡¡¡¡¦¡¦¡¦ÂçIJ´â¼£ÎŤοÊÊâ¡¡¡¡
·àŪ¤ÊÊÑÁ«¤Î²áÄø¤òºÇ¤âüŪ¤Ë¼¨¤·¤Æ¤¤¤ë¿Ê¹Ô¤¬¤ó¤Î¼£ÎÅÀ®ÀӤˤĤ¤¤Æ¡¦¡¦ ¢¡ | ÂçIJ´â ¾ |
 |
 | ²½³ØÎÅË¡¡¡¡¦¡¦¡¦¡¦ÇÙ¾®ºÙ˦´â¤Î²½³ØÎÅË¡¡¡
ɸ½à²½³ØÎÅË¡¡¡£Ì£Ä¾ÉÎã¤ËÂФ¹¤ëÊü¼ÍÀþ²½³ØÎÅË¡¡¡
¡¦ÇÙ¡¦¡¦ ¢¡ | 58-05 ¾ |
 |
 | ²½³ØÎÅË¡¡¡¡Ý´ÎºÙ˦´â¤Î¼£ÎŤοÊÊâ¡¡¡¦¡¦¡¦²½³ØÎÅË¡¤Î°ÌÃÖÉÕ¤±
Î×¾²»î¸³¤ÎÀ®ÀÓ¡¡
¡¦¡¦¡¦
ʬ»ÒɸŪ¼£ÎÅÌô¤òÃæ¿´¤È¤·¤¿¿·µ¬¹³´âºÞ¡¦¡¦ ¢¡ | ´Î¡´â ¾ |
 |
 | ²½³ØÎÅË¡¡¦Êü¼ÍÀþÎÅË¡¤Ë¤è¤ê¡¤Æð¹ü¤Ø¤Îʬ²½¤¬Ð¶¿Ê¤·¤¿¤È¹Í¤¨¤é¤ì¤¿¶»ËìÇÙ²ê¼ð¤Î1Îã ¢¡ | 9·î£´½µ¡Ê24Æü¡Ë ¾ |
 |
 | ²½³ØÎÅË¡¤¬ÁÕ¸ú¤·2ǯ¤ÎÀ¸Â¸¤¬ÆÀ¤é¤ì¤¿ÇÙž°Ü¤òȼ¤¦ÀÚ½üÉÔǽ繴â¤Î1Îã ¢¡ | £³·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | ¢¡3737 | ²½³ØÎÅË¡ ¾ |
 |
 | ²½³ØÎÅË¡¤¬Ãø¸ú¤·º¬¼£ÀÚ½ü²Äǽ¤È¤Ê¤Ã¤¿Ê¢ËìÇżïÍÛÀ°ß´â¤Î1Îã ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | ²½³ØÎÅË¡¤¬Ìµ¸ú¤Ç¤¢¤Ã¤¿ç¯æù´â¥ê¥ó¥ÑÀឰܤβ¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎÅ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² |
 |
 | ²½³ØÎÅË¡¤¬Ìµ¸ú¤Êç¯æù´â¥ê¥ó¥ÑÀឰܤËÂФ¹¤ë²¹Ç®Êü¼ÍÀþ¼£ÎÅ ¢¡ | 15-Supplement¡¡µ ¾ |
 |
 | ²½³ØÎÅË¡¤Ç¼ê½Ñ²Äǽ¤È¤Ê¤Ã¤¿º¸Ë¼¿»½áÇÙ´â¤Î1Îã ¢¡ | ÇÙ´â ¾ |
 |
 | ²½³ØÎÅË¡¤Ç¾Ã¼º¤·¤¿ÇÙ¾®ºÙ˦´â°ßž°Ü¤Î1Îã¡¡¡¦¡¦¡¦¾ÉÎã¡¡66ºÐÃËÀ¡¡
¹Í»¡¡¡¡¦¡¦ ¢¡ | ¾®ºÙ˦´â ¾ |
 |
 | ²½³ØÎÅË¡¤ÇÁÈ¿¥·¿¤ò¹Íθ¤¹¤Ù¤¤« -ÍñÁ㤬¤ó ¢¡ | ÍñÁã´â ¾ |
 |
 | ²½³ØÎÅË¡¤È¼£¸³¥³¡¼¥Ç¥£¥Í¡¼¥¿¡¼(Clinical Research Coordinator) | 31-01 |
 |
 | ²½³ØÎÅË¡¤Ë¤Æ´°Á´´²²ò¤¬ÆÀ¤é¤ì23¤«·îÀ¸Â¸¤·¤¿Stage IVb¿©Æ»¾®ºÙ˦´â¤Î1Îã ¢¡ | ¿©Æ»´â ¾ |
 |
 | ²½³ØÎÅË¡¤Ë¤è¤ê2ǯ°Ê¾å¤Ë¤ï¤¿¤Ã¤Æ¼«³Ð¾É¾õ¤Ê¤¯Îɹ¥¤ÊPS¤¬ÆÀ¤é¤ì¤¿¹âÎð¼ÔStage IV°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | ²½³ØÎÅË¡¤Ë¤è¤êͽ¸å¤Î²þÁ±¤¬ÆÀ¤é¤ì¤¿Î¾Â¦ÍñÁã,¿ȯÈéÉæ,¹üž°Ü¤òȼ¤¦°ßsm´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | ¢¡3739 | Êü¼ÍÀþ´ØÏ¢ ¾ |
 |
 | ²½³ØÎÅË¡¤Ëȼ¤¦¿´ÆÇÀ¤Î´ÉÍý¡¡¡¦¡¦¡¦¥¢¥ó¥¹¥é¥µ¥¤¥¯¥ê¥ó·ÏÌôºÞ¡¡¥É¥¥½¥ë¥Ó¥·¥ó¡¡¥¨¥Ô¥ë¥Ó¥·¥ó
¥¿¥¥µ¥ó·ÏÌôºÞ¡¡¥Ñ¥¯¥ê¥¿¥¥»¥ë¡¦¡¦ ¢¡ | áÖÄË¡¦´ËÏ ¾ |
 |
 | ²½³ØÎÅË¡¤ÎÍÍÑÀ¤¬¼¨º¶¤µ¤ì¤¿¾®»ùChoroid Plexus Carcinoma¤ÎĹ´üÀ¸Â¸Îã ¢¡ | ¾®»ù´â ¾ |
 |
 | ²½³ØÎÅË¡³«»Ïľ¸å¤ËÀü¹¦¤ò¤¤¿¤·¤¿°ß¸¶È¯°À¥ê¥ó¥Ñ¼ð¤Î1Îã ¢¡ | °À¥ê¥ó¥Ñ¼ð ¾ |
 |
 | ²½³ØÎÅË¡¸åµÞ·ã¤Ë¹³ÍøÇ¢¥Û¥ë¥â¥óʬÈç°Û¾ï¾É¸õ·²¤òÍ褷¤¿1Îã ¢¡ | £²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | ²½³ØÎÅË¡»þ¤Î¸ýÆâ±ê¤ËÂФ¹¤ë¾®¼Æ¸ÕÅò´ÞÓÖ±Õ¤ÎÍÍÑÀ ¢¡ | áÖÄË¡¦´ËÏ ¾ |
 |
 | ²½³ØÎÅË¡ÉÔ±þÀ¤Î¿ȯÀ¹ü¿ñ¼ð¤ËÂФ¹¤ë¼«²ÈËö¾¿·ì´´ºÙ˦°Ü¿¢Ê»ÍÑÂçÎ̲½³ØÎÅË¡¤Î»î¤ß ¢¡ | ·ì±Õ¡¦¥ê¥ó¥Ñ ¾ |
 |
 | ²½³ØÎÅˡʻÍѤˤè¤ëº¬¼£Åª¼£ÎÅ-¿©Æ»´â-¾È¼ÍÌîÊýË¡¤Î¸¡Æ¤ ¢¡ | Êü¼ÍÀþ´ØÏ¢ ¾ |
 |
 | ²Ã²¹Ãæ¤ËÅŶ˥ܡ¼¥é¥¹¿å¤Î²ÃÇ®¡¢Ï³¿å¤Ë¤è¤êÇ®½ý¤òÀ¸¤¸¤¿1Îã | 22²ó¡¡Âç²ñ |
 |
 | ²È²¤ò¤¬¤ó¤Ç¼º¤Ã¤¿¿Í¡¹¤Î¿´¤Î¥±¥¢¡¡¡¦¡¦¡¦°ä²¥±¥¢¤ÎɬÍ×À¡¡
Èá´Ñ¤Î¿´Íý²áÄø¡¡ÉÂŪÈá´ÑÈ¿±þ¡¡²È²¥¢¥»¥¹¥á¥ó¥È
»àÊ̤Τµ¤Þ¤¶¤Þ¤Ê¡¦¡¦ ¢¡ | 9·î£³½µ¡Ê£±£¶Æü¡Ë ¾ |
 |
 | ²È²À gastrointestinal stromal tumor¡ÊGIST¡Ë ¢¡ | GIST ¾ |
 |
 | ²È²ÀWilms¼ðáç¤Î·»ÄïÎã¡¡¡¦¡¦¡¦²È²Îò¡¡
¾ÉÎã¡¡·»4ºÐ1¤«·î,ÃË»ù¡¡
¹Í»¡¡¡¡¦¡¦ ¢¡ | £¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾ |
 |
 | ²È²À¼ðáç¤Î°äÅÁ¥«¥¦¥ó¥»¥ê¥ó¥°¤Î¼ÂºÝ¤È²ÝÂê ¢¡ | Cancer Frontier Vol.4 ¾ |
 |
 | ²È²À¼ðá縦µæ-²ó¸Ü¤ÈŸ˾-¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | 2006ǯ1·î ¾ |
 |
 | ²È²ÀÂçIJÁ£¼ð¾É¤È³«Ê¢´û±ý¤Î¤Ê¤¤¾®Ä²Ä²´ÖËìÀþ°Ý¼ð¤Î 1 Îã ¢¡ | ÂçIJ´â ¾ |
 |
 | ²È²Æâ´¶À÷¤¬µ¿¤ï¤ì¤¿H. pyloriÍÛÀ3²È²¤ÎRandom Amplhied Polymorphic DNAË¡¤Ë¤è¤ë¸¡Æ¤ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | ¢¡3743 | ÉûºîÍÑ Â¾ |
 |
 | ²Ê³ØÅªº¬µò¤Ë´ð¤Å¤¤¤¿·ì¾®Èĸº¾¯¤ÎÂнèË¡¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | ÉûºîÍÑ Â¾ |
 |
 | ²Ê³ØÅªº¬µò¤Ë´ð¤Å¤¤¤¿¹¥Ãæµå¸º¾¯¤ÈȯǮ¤ÎÂнèË¡ ¢¡ | ÉûºîÍÑ Â¾ |
 |
 | ²Ú²¬ÀĽ§¤ò¤á¤°¤ë»ËÏÃ;Ͽ¡¡¡¦¡¦¡¦°å³Ø»Ë¿ïÁÛ¡¡¡¡¡¡¡¡
1.²Ú²¬Î®ËãʨÅò¤Î´æºî¡Ý¤â¤¦°ì¤Ä¤Î¡ÖËãÌô¹Í¡×¡Ý¡¡
2.Ä²Ú²¬¼¯¡¦¡¦ | 19-01 |
 |
 | ²áµî5ǯ´Ö¤Î¼ª²¼Á£¼ðáçÅý·×¡¡¡¦¡¦¡¦¼ª²¼Á£¼ðáç40¾ÉÎã
·ë²Ì
¹Í»¡¡¦¡¦ ¢¡ | 8·îÂè2½µ(5Æü¡Ë ¾ |
 |
 | ²á¸í¼ðÀ¥Ý¥ê¡¼¥×¤«¤é¿ÊŸ¤·¤¿¤È¹Í¤¨¤é¤ì¤ë»Ä°ß´â¤ò¹çÊ»¤·¤¿Peutz-Jeghers¾É¸õ·²¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | ²áÉҾɡ¡¡¦¡¦¡¦¿·¤·¤¤Í³²È¿±þÂкö¡¦¡¦ ¢¡ | ÉûºîÍÑ Â¾ |
 |
 | ²áÉÒÈ¿±þ¡¡¡¦¡¦¡¦¹³´âºÞ¼£ÎŤˤª¤±¤ë²áÉÒÈ¿±þ¡¡
¥¿¥¥µ¥ó·ÏÌôºÞ¡¡¥Ñ¥¯¥ê¥¿¥¥»¥ë¡¡¥É¥»¥¿¥¥»¥ë¡¡¥Ï¡¼¥»¥×¥Á¡¦¡¦ ¢¡ | áÖÄË¡¦´ËÏ ¾ |
 |
 | ²èÁü½ê¸«¾å¼ðáçÀÉÂÊÑ¤ÎÆ±Ä꤬º¤Æñ¤Ç¤¢¤Ã¤¿¤Ó¤Þ¤ó·¿ ´Î·ì´ÉÆù¼ð¤Î1Îã ¢¡ | 9·îÂ裱½µ¡Ê1Æü¡Ë ¾ |
 |
 | ²èÁü¾åÆý´â¤È¤Î´ÕÊ̤˶ìθ¤·¤¿Ductal Adenoma¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | ²èÁü¿ÇÃÇ¡¡¡¦¡¦¡¦PET¡¡MDCT¡¦¡¦¡ÝºÇ¶á¤Î¿ÊÊâ¡Ý
ÇÙ´â¿ÇΚݺǶá¤ÎÏÃÂê¡Ý¡¦¡¦ ¢¡ | ÇÙ´â ¾ |
 |
 | ²èÁü¿ÇÃǤοÊÊ⡽PET¡¤SPECT¡¤CT¡¤MR ³È»¶¶¯Ä´²èÁü¡½ ¢¡ | °À¥ê¥ó¥Ñ¼ð ¾ |
 |
 | ²èÁü¿ÇÃǤÏPathological CR¤ò¿äÄê¤Ç¤¤ë¤« | 20-05 |
 |
 | ²ò˶³Ø¡¦ÁÈ¿¥³Ø¤«¤é¤ß¤¿¥»¥ó¥Á¥Í¥ë¥ê¥ó¥ÑÀá¼êË¡ ¢¡ | ¥»¥ó¥Á¥Í¥ë¥ê¥ó¥ÑÀá ¾ |
 |
 | ²óIJËöüÉô¤Î¶¹ºõÀÉÂÊѤοÇÃÇÃæ¤ËÀü¹¦¤ò¤¤¿¤·¤¿²óIJ°À¥ê¥ó¥Ñ¼ð¤Î1Îã ¢¡ | °À¥ê¥ó¥Ñ¼ð ¾ |
 |
 | ²þÎÉ·¿PMCTÅŶË(PERCUPR0)¤òÍѤ¤¤¿¾®´Î´â¤ËÂФ¹¤ë¥Þ¥¤¥¯¥íÇȶŸǼ£ÎŤÎÍÍÑÀ¤Ë¤Ä¤¤¤Æ ¢¡ | 18-Supplement ¾ |
 |
 | ³¤³°¤ÈÈæ¤Ù¤¿»þ¤Î¥¤¥ó¥¿¡¼¥Õ¥§¥í¥óÎÅË¡¤Î¸½¾õ¤Èº£¸å¤ÎŸ˾ ¢¡ | ´Î¡´â ¾ |
 |
 | ³¤»ºÀ¹³¤¬¤óʪ¼Á¤Î³«È¯¸½¶·¡¡¡¦¡¦¡¦Aplidine ES-285 kahalalide F Aplidine Ectein¡¦¡¦ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | ³«¶»³«Ê¢¤Ë¤è¤ë¶»Éô¿©Æ»´â¼ê½Ñ¡¡¡¦¡¦¡¦ÇíÎ¥ÃÇü´â±¢À
¡¡¶»Éô¿©Æ»´âº¬¼£¼ê½Ñ¡¡
¡¡¡¦¡¦ ¢¡ | ¿©Æ»´â ¾ |
 |
 | ³«¶»½Ñ¸å¤ÎáÖÄˤËÂФ¹¤ë»ý³Ͼ´Ö¿À·Ð¥Ö¥í¥Ã¥¯¤Î͸úÀ ¢¡ | £²·îÂ裴½µ¡§£²£µÆü¡Ê¶â¡Ë ¾ |
 |
 | ³°±¢¡¦çµ´â¡Ê٨ʿ¾åÈé¡Ë¡¡BOMP7¡¡¡¦¡¦¡¦....
¡¡´í¸±ÅÙ
¡¡¹³´âºÞŬ±þʬÎà
¡¡1ÆüÅêÍ¿ÎÌ¡¡ÅêͿˡ¡¢´ü´Ö¡¢ÅêÍ¿Æü
¡¡Ãæ»ß¡¦¡¦ | ި޽ޏÊ̤¬¤ó²½³ØÎÅË¡ŽÚ޼ŽÞŽÒŽÝ |
 |
 | ³°±¢´â¤Î¼è¤ê°·¤¤Update¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | ÉØ¿Í²Ê ¾ |
 |
 | ³°±¢´â¼£ÎÅ -ºÇ¶á¤Î¿ÊÊâ-¡¡¡¦¡¦¡¦ÉؿͲʴ⼣ÎŤοÊÊ⡦¡¦ ¢¡ | 2·î ¾ |
 |
 | ³°±¢Éô¸¶È¯¤Î°À¹õ¿§¼ð¤Î2Îã¡¡¡¦¡¦¡¦³°±¢Éô¤Ë¸¶È¯¤·¤¿°À¹õ¿§¼ð¤Î£²Îã¤ò·Ð¸³¤·¤¿¤Î¤Ç¼ã´³¤Îʸ¸¥Åª¹Í»¡¤ò²Ã¤¨¤ÆÊó¹ð¡£¡¡¡¡
¡¡
¡¦¡¦ ¢¡ | °À¹õ¿§¼ð ¾ |
 |
 | ³°²Ê¤«¤é¸«¤¿¥Ð¥ì¥Ã¥È¾åÈé¤È¥Ð¥ì¥Ã¥ÈÁ£´â¡¡¡¦¡¦¡¦¥Ð¥ì¥Ã¥È¾åÈé¤È¥Ð¥ì¥Ã¥ÈÁ£´â¤ÎÎ×¾²¿ÇÃÇ
¥Ð¥ì¥Ã¥ÈÁ£´â¤È¿©Æ»°ßÀܹçÉôÁ£´â
Æâ»ë¶À¤ª¤è¤Ó³°¡¦¡¦ ¢¡ | ¿©Æ»´â ¾ |
 |
 | ³°²Ê°å¤¬¹Í¤¨¤ëç¹´â¤Î¼ê½ÑŬ±þ¡¡¡¦¡¦¡¦ç¹´â¤ËÂФ¹¤ë¼£ÎÅÊý¿Ë¤Î¿ä°Ü¡¿½Ñ¸åÀ®ÀÓ¡¿ç¹´âÁ´¹ñÅÐϿĴººÊó¹ð¤Ë¤è¤ë¸¡Æ¤¡¿ÈóÀÚ½üç¹´â¤ËÂФ¹¤ë¡¦¡¦ | 76 |
 |
 | ³°²Ê°å¤ÎΩ¾ì¤«¤é¤ß¤¿¥ê¥ó¥ÑÉâ¼ð¤Î¸½¶·¡¡¡¦¡¦¡¦ÊÝ¸Ū¼£ÎÅË¡
¡¡Ê£¹çŪ¡¦Íý³ØÅª¤¦¤ÄÂÚ½üµîÎÅË¡(Complex Decongestive¡¦¡¦ ¢¡ | £²·îÂ裴½µ¡§£²£µÆü¡Ê¶â¡Ë ¾ |
 |
 | ³°²Ê¼ê½ÑÀ®ÀÓ¤«¤é¤ß¤¿¿©Æ»´â¼£ÎŤˤª¤±¤ë²½³ØÊü¼ÍÀþÎÅË¡¤ÎŬ±þ¤È°ÕµÁ ¢¡ | ¿©Æ»´â ¾ |
 |
 | ³°²ÊŪÀÚ½ü¤ò¹Ô¤Ã¤¿»éËòê¼ð7Îã¤Î¸¡Æ¤¡¡¡¦¡¦¡¦ÂоݤÈÊýË¡¡¡7¾ÉÎã¡¡11¥ö·î¡Á9ºÐ1¥ö·î¡¡
¡¡¡¡»éËòê¼ð¡¡
·ë²Ì¡¡¡¡
¹Í»¡¡¡¡¦¡¦ ¢¡ | £¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾ |
 |
 | ³°¼ª¤ÎÁ£´â¡¡¡¦¡¦¡¦¾ÉÎã¡¡³°¼ªÆ»´â
¡¡£¸£³ºÐÃËÀ¡¡Á£´â
¡¡¡¡£¶£³ºÐÃËÀ¡¡
¡¡£³£¶ºÐÃËÀ¡¡Á£ÍÍǹ˦´â¡¡
¡¦¡¦ ¢¡ | 9·î£´½µ¡Ê24Æü¡Ë ¾ |
 |
 | ³°¼ªÆ»Á£ÍÍǹ˦´â¤Î¿ȯÀÇÙž°Ü¤ËTS-1¤¬ÁÕ¸ú¤·¤¿1Îã ¢¡ | ÂñÕÁ£´â ¼ª²¼Á£´â¡¡ ¾ |
 |
 | ³°Íè¤Ç¤ÎWeekly PaclitaxelÎÅË¡¤ÇĹ´ü´Ö¤Î´²²ò¤¬ÆÀ¤é¤ì¤¿IV´üÈ󾮺Ù˦ÇÙ´â¤Î1Îã ¢¡ | È󾮺Ù˦´â ¾ |
 |
 | ¢¡3741 | ²½³ØÎÅË¡ ¾ |
 |
 | ¢¡3740 | ²½³ØÎÅË¡ ¾ |
 |
 | ³°Íè²½³ØÎÅË¡¤Ë¤ª¤±¤ë¸ý¹ÐÆâÊø²õÀ©ÅǺÞÅêÍ¿¤ÎQOLɾ²Á ¢¡ | áÖÄË¡¦´ËÏ ¾ |
 |
 | ³°Íè²½³ØÎÅË¡¤Îή¤ì¤Ë»×¤¦¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | ³°Íè²½³ØÎÅË¡¤Ï¤É¤¦¤¢¤ë¤Ù¤¤«¡¡¡¦¡¦¡¦³°Íè²½³ØÎÅË¡¤Ë°Ü¹Ô¤¹¤ë¤ËÅö¤¿¤Ã¤Æ
¾Ý¼À´µ¡¦¼£ÎÅÆâÍÆ
¥á¥ê¥ÃËΡ¦¥Ç¥á¥ê¥ÃËÎ
Åö±¡¡¦¡¦ ¢¡ | £´·îÂ裱½µ¡§£²Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | ³°Íè²½³ØÎÅË¡¼¼¤Ë¤ª¤±¤ë10¼ïÎà¤Î24G(¥²¡¼¥¸)¥«¥Æ¡¼¥Æ¥ë·¿ÀÅÌ®ÆâαÃֿˤÎÁàºîÀ¤È°ÂÁ´À¤Îɾ²Á ¢¡ | ¼êµ»¡¦¡¦ ¾ |
 |
 | ³°Íè²½³ØÎÅË¡¼¼¾Ò²ð¤ËÅö¤¿¤Ã¤Æ¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | ³°Íè´ÎưÃí²½³ØÎÅË¡¤ª¤è¤ÓÁ´¿È²½³ØÎÅˡʻÍѤˤÆ5ǯÀ¸Â¸¤·ÆÀ¤¿¾å¹Ô·ëIJ´â¿ȯÀ´Îž°ÜÊ¢ËìÇżï¤Î1Îã ¢¡ | ´âÀÊ¢Ëì±ê ¾ |
 |
 | ¢¡3728 | ²½³ØÎÅË¡ ¾ |
 |
 | ³°Íè´â²½³ØÎÅË¡¤Î¼ÂºÝ¤ÈÌäÂêÅÀ¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | Á°Î©Á£´â ¾ |
 |
 | ³°Íè¼£ÎŤˤè¤êCPT-11/5-FU/l-LV(IFL)ÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿´Î¡¦ÇÙž°Ü¤òȼ¤¦ÂçIJ´â¤Î1Îã ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | ³°ÍèÄ̱¡¤¬¤ó¼£ÎŤ˴ؤ¹¤ë2002ǯÅÙÁ´¹ñɱ¡Ä´ºº·ë²ÌÊó¹ð ¢¡ | £··îÂ裴½µ¡§£²£´Æü¡ÊÆü¡Ë ¾ |
 |
 | ³°ÍèÄ̱¡¤Ë¤Æ²½³ØÎÅË¡¤ÈÊü¼ÍÀþÎÅË¡¤ò»Ü¹Ô¤·¤¿¿ÕÉÔÁ´¤ò¹çÊ»¤·¤¿ºÆÈ¯Æý´â¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | ³°ÍèÅêÍ¿¤ÇTS-1/ÄãÍÑÎÌCPT-11´ÎưÃíÊ»ÍÑÎÅË¡¤¬ÍÍѤǤ¢¤Ã¤¿ÂçIJ´â¿ȯ´Îž°Ü¤Î1Îã ¢¡ | ·ëIJ´â ¾ |
 |
 | ³Æ¼ïô»Ò¶ÝÀ½ºÞ¤Î¶É½êÅêÍ¿¤Ë¤è¤ë¹³¼ðáç¸ú²Ì¤Îº¹°Û ¢¡ | ¿©À¸³è ¾ |
 |
 | ³ÈÂç¼ê½Ñ¤ÈEAP²½³ØÎÅË¡¤Ë¤è¤Ã¤ÆÄ¹´ü̵ºÆÈ¯À¸Â¸¤¬ÆÀ¤é¤ì¤¿Ê¢ÉôÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀáÃøÌÀž°Ü¤òȼ¤Ã¤¿°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | ³Ü²¼Á£¤ÎÁ£´â¡¡¡¦¡¦¡¦³Ü²¼Á£´â
¾ÉÎã¡¡£¶£µºÐ½÷À¡¡
¡¡£¶£·ºÐ¡¡ÃËÀ¡¡
¹Í»¡¡¡ÉÂÍýÁÈ¿¥Ê¬Îà¡¡¿ÇÃÇ¡¡¼£ÎÅ¡¡
¡¦¡¦ ¢¡ | ƬðôÉô ¾ |
 |
 | ³Ü²¼Á£·ì´É¼ðÎã¡¡¡¦¡¦¡¦¾ÉÎã:46ºÐ,½÷À¡¦¡¦ ¢¡ | ƬðôÉô ¾ |
 |
 | ³Ü²¼Á£ÂÃÀФ˹çÊ»¤·¤¿Ù¨Ê¿¾åÈé´âÎã¡¡¡¦¡¦¡¦¾ÉÎã¡¡£µ£¸ºÐ¡¡ÃËÀ¡¡¡¦¡¦ ¢¡ | ƬðôÉô ¾ |
 |
 | ³èÀúµÛÃåMethotrexate(MTX-CH)¶É½êÅêÍ¿¤Î´ðÁÃŪ¸¡Æ¤ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | ³èÀúµÛÃåMethotrexate(MTX-CH)¼ðáçÆâÃíÆþÎÅË¡¤ÎÍÍÑÀ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | ³èÀúµÛÃåMitomycin CÊ¢¹ÐÆâÅêÍ¿¤Ë¤è¤êÊ¢¿å¤òͤ¹¤ë°ß´âÊ¢ËìºÆÈ¯¤Î¼£ÎÅ4¾ÉÎã¤Î¸¡Æ¤ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | ³êËìÆù¼ð¤ËÂФ¹¤ëÊü¼ÍÀþ²¹Ç®²½³ØÎÅË¡¤Î¸¡Æ¤¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | 21-Supplement ¶ ¾ |
 |
 | ³êËìÆù¼ð¤Î¶»¹ÐÆâž°Ü¤ËÂФ·¶»ËìÇÙÁ´Å¦½Ñ¤ò¹Ô¤Ã¤¿1Îã ¢¡ | £±£°·î£±Æü£Õ£Ð ¾ |
 |
 | ´¶À÷¾É¡¡¡Ý¼À´µÊ̤ˤߤ¿DIC¤ÎÉÂÂÖ¡¡¡¦¡¦¡¦SIRS
´¶À÷¾ÉDIC¡¡±Ö³Ø¡¡ÆÃħ¡¡
¸¡ºº¾å¤ÎÃí°Õ¡¡¡¦¡¦ ¢¡ | DIC ¾ |
 |
 | ´ÁÊý¼£ÎŤ¬ÁÕ¸ú¤·¤¿Ä°¿À·Ð¼ðáç¤Î1¾ÉÎã¡¡¡¦¡¦¡¦¡¡¾ÉÎã¡¡75ºÐ,½÷À¡¡
¡¡¡¡º¸Ä°¿À·Ð¼ðáç¡¡¡¡¥¬¥ó¥Þ¥Ê¥¤¥Õ¡¡
¤á¤Þ¤¤âÁÚô¡¡¥á¥Þ¥¤
¡¡¡¦¡¦ ¢¡ | 9·î£´½µ¡Ê24Æü¡Ë ¾ |
 |
 | ´Ç¸î¤Ë¤ª¤±¤ëÌôʪͳ²È¿±þÂкö¡¡¡¦¡¦¡¦¹³Çò·ìÉÂÌô¤Ë¤è¤ë¹ü¿ñµ¡Ç½ÍÞÀ©¡¡
¹ü¿ñÀ©¸æ¤ËÂФ¹¤ë´Ç¸î¡¡
̵¶Ý¥¾¡¼¥ó¤Ë¤Ä¤¤¤Æ
¸ý¹ÐÆâ¡¦¡¦ ¢¡ | £¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾ |
 |
 | ´ËÏÂ¥±¥¢ ¡Ý¥¿¡¼¥ß¥Ê¥ë¥±¥¢¡¡¡¦¡¦¡¦´ËϰåÎŤÎÌÜŪ¡¡
³Æ¿¦¼ï¤ÎÌò³ä¡¡´ËÏÂ¥±¥¢¤ÎÂоݡ¡
½ªËö´ü»þ¤Î¥±¥¢¡¡É԰¡¡ÉÔ̲¡¡Ýµ¾õÂÖ¡¦¡¦ ¢¡ | 9·î£³½µ¡Ê£±£¶Æü¡Ë ¾ |
 |
 | ´ËÏÂ¥±¥¢¤Î²ÝÂê¤È¾Íè¡¡¡¦¡¦¡¦´ËÏÂ¥±¥¢¤ÎÌÜŪ¤Ë¸ÄÊ̤˸ÄÊÌÀ¤òÈ¿±Ç¤µ¤»¤ë¡¡
ÀìÌç´ËÏÂ¥±¥¢¤ØÅ¬Àڤʻþ´ü¤Ë¾Ò²ð¤Ç¤¤ë¥·¥¹¥Æ¡¦¡¦ ¢¡ | £³·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | ´ËϰåÎŤȴÁÊý¡¡¡¦¡¦¡¦´ÁÊý¼£ÎŤΰյÁ¡¡
´ÁÊýÊäºÞ
¾É¾õ¤Î´ËÏ¡¡¸ýÆâ±ê¡¡Àå±ê¡¡¸ý³é¡¡¸ý¹ÐÆâ´¥Áç¡¡°¿´¡¡ÓÒÅÇ.¡¦¡¦ ¢¡ | áÖÄË¡¦´ËÏ ¾ |
 |
 | ´ËϰåÎŤˤª¤±¤ë´â²½³ØÎÅË¡¤Î²ÄǽÀ¡¡¡¦¡¦¡¦£²£·¾ÉÎã
´ËϤÎÌÕÅÀ¡¡
´ËϰåÎŴĶ¤Ë¤ª¤±¤ë¡¡Palliative chemot¡¦¡¦ ¢¡ | áÖÄË¡¦´ËÏ ¾ |
 |
 | ´ËÏÂŪÊü¼ÍÀþ¼£ÎÅ-Ǿž°Ü,¹üž°Ü¤Ø¤ÎÊü¼ÍÀþ¼£ÎŤοÊÊâ ¢¡ | Êü¼ÍÀþ´ØÏ¢ ¾ |
 |
 | ´Î¡¦ÃÀÆ»¡¦ç¹¼ðáç¤ËÂФ¹¤ë²¹Ç®Êü¼ÍÀþÎÅË¡¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | 19-Supplement¡¡¶ ¾ |
 |
 | ´Î¡¦ÇÙ¡¦¹ü¤ËÂФ¹¤ëRFA:½é´ü¼£ÎŸú²Ì¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | 21-Supplement µ ¾ |
 |
 | ´Î¤ª¤è¤Óç¹´âºÙ˦³ô¤Ë¤ª¤±¤ë¥±¥â¥«¥¤¥ó¥ì¥»¥×¥¿¡¼mRNA¤Îȯ¸½ | 31-08 |
 |
 | ´Î¤¬¤ó¼£ÎŤÎControversy-³°²Ê¤ÎΩ¾ì¤«¤é- ¢¡ | ´Î¡´â ¾ |
 |
 | ´Î¤¬¤ó¼£ÎŤÎControversy-Æâ²Ê¤ÎΩ¾ì¤«¤é- ¢¡ | ´Î¡´â ¾ |
 |
 | ´Î¤Ë½éȯ¤·½Ñ¸å10ǯÌܤÇ繤ˤâǧ¤á¤é¤ì¤¿ÎÏ¥ë¥Á¥Î¥¤¥É¼ðáç¤Î1˶¸¡Îã ¢¡ | £¸·î£±Æü ¾ |
 |